PMID- 10707776
OWN - NLM
STAT- MEDLINE
DCOM- 20000330
LR  - 20161017
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 11 Suppl 1
DP  - 2000
TI  - Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in 
      young persons.
PG  - 35-8
AB  - INTRODUCTION: Burkitt-like lymphoma (BLL) is a provisional category of B-cell 
      lymphoma which is morphologically intermediate between Burkitt lymphoma (BL) and 
      large B-cell lymphoma (LBCL). The clinical significance of this morphology is 
      controversial. PATIENTS AND METHODS: We examined 41 cases of pediatric B-cell 
      lymphoma by immunohistochemistry for proteins associated with proto-oncogenes 
      c-myc, BCL-2 and BCL-6 and a subset of cases (with adequate slides) for a 
      proliferation-associated marker (Ki-67) and for apoptosis (Apop-Tag). Sixteen 
      cases of BLL, thirteen cases of BL and twelve cases of LBCL were examined. 
      RESULTS: Our results showed BCL-6 expression in 16 of 16 BLL, 4 of 13 BL, and 9 
      of 12 LBCL; c-myc expression in 14 of 15 BLL, 9 of 13 BL, and 12 of 12 LBCL; and 
      BCL-2 expression in 2 of 16 BLL, 9 of 13 BL, and 6 of 12 LBCL. Mean apoptotic 
      index for BLL was 10.3% (n = 6); for BL was 17.1% (n = 5); and for LBCL was 10.9% 
      (n = 6). Ki-67 was diffusely reactive in all cases tested. There was a 
      significantly higher proportion of BLL than BL which expressed BCL-6 (P = 
      0.0001). CONCLUSIONS: Labeling for BCL-6 distinguishes BLL from BL. It is likely 
      that in children in North America, BLL is biologically distinct from BL and more 
      closely resembles a subset of LBCL.
FAU - Hutchison, R E
AU  - Hutchison RE
AD  - State University of New York Health Science Center, Syracuse, USA.
FAU - Finch, C
AU  - Finch C
FAU - Kepner, J
AU  - Kepner J
FAU - Fuller, C
AU  - Fuller C
FAU - Bowman, P
AU  - Bowman P
FAU - Link, M
AU  - Link M
FAU - Schwenn, M
AU  - Schwenn M
FAU - Laver, J
AU  - Laver J
FAU - Desai, S
AU  - Desai S
FAU - Barrett, D
AU  - Barrett D
FAU - Murphy, S B
AU  - Murphy SB
LA  - eng
GR  - CA-29139/CA/NCI NIH HHS/United States
GR  - CA-33603/CA/NCI NIH HHS/United States
GR  - CA-33625/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Adolescent
MH  - Biomarkers, Tumor/*analysis
MH  - Burkitt Lymphoma/diagnosis/*pathology
MH  - Child
MH  - Child, Preschool
MH  - DNA-Binding Proteins/*analysis
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Immunophenotyping
MH  - Lymphoma, Large B-Cell, Diffuse/diagnosis/*pathology
MH  - Male
MH  - Prognosis
MH  - Proto-Oncogene Proteins/*analysis
MH  - Proto-Oncogene Proteins c-bcl-2/*analysis
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Sensitivity and Specificity
MH  - Transcription Factors/*analysis
EDAT- 2000/03/09 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/09 09:00
PHST- 2000/03/09 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/09 09:00 [entrez]
PST - ppublish
SO  - Ann Oncol. 2000;11 Suppl 1:35-8.